

## A Single Amino Acid Exchange, Arg-45 to Ala, Generates an Epidermal Growth Factor (EGF) Mutant with High Affinity for the Chicken EGF Receptor\*

(Received for publication, April 21, 1995, and in revised form, June 27, 1995)

Monique L. M. van de Poll‡, Anne E. G. Lenferink, Marianne J. H. van Vugt, Jacqueline J. L. Jacobs, Jannie W. H. Janssen, Manon Joldersma, and Everardus J. J. van Zoelen

From the Department of Cell Biology, University of Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands

The finding that human epidermal growth factor (hEGF) and human transforming growth factor (hTGF)  $\alpha$  bind with similar affinity to the human EGF receptor but differ in their affinity for the chicken EGF receptor was used as a model system to study ligand-receptor interaction of EGF receptor agonists. We previously constructed domain-exchange mutants of hEGF and hTGF $\alpha$  and found that the region COOH-terminal of the sixth cysteine residue in hTGF $\alpha$  is important for high affinity binding to the chicken EGF receptor (Kramer, R. H., Lenferink, A. E. G., Lammerts van Bueren-Koornneef, I., van der Meer, A., van de Poll, M. L. M., and van Zoelen, E. J. J. (1994) *J. Biol. Chem.* 269, 8708–8711). To analyze this domain in more detail, we now constructed four additional chimeras in which either the region between the sixth cysteine residue and the highly conserved Leu-47 was exchanged or the region COOH-terminal of Leu-47. A mutant in which the latter region in hEGF was replaced by hTGF $\alpha$  (designated E6ET) showed intermediate binding affinity, whereas replacement of the former region in hEGF by hTGF $\alpha$  was sufficient to generate a mutant (designated E6TE) with a similar high affinity for the chicken EGF receptor as wild type hTGF $\alpha$ . Furthermore, a deletion mutant of hEGF lacking three COOH-terminal amino acids, EGF50, showed intermediate binding affinity for the chicken EGF receptor similar to E6ET, but upon additional deletions (EGF49 and EGF48), this initial gain in affinity was lost. A systematic analysis of the region between the sixth cysteine residue and Leu-47 showed that the low affinity of hEGF for the chicken EGF receptor is mainly due to the presence of Arg-45. Replacement of the positively charged Arg-45 by Ala, the corresponding amino acid in hTGF $\alpha$ , was sufficient to generate a mutant growth factor with high affinity for the chicken EGF receptor. This indicates that in hEGF Arg-45 may play an important role in receptor binding. A model is proposed in which positively charged amino acids close to or within the receptor recognition site of hEGF prohibit high affinity binding to the chicken EGF receptor due to electrostatic repulsion of positively charged amino acids in the putative ligand binding domain of the chicken EGF receptor.

Human epidermal growth factor (hEGF)<sup>1</sup> and human transforming growth factor (hTGF)  $\alpha$  belong to the same family of growth factors. They both bind with high affinity to the human EGF receptor, but hEGF has a 10–50-fold lower affinity for the chicken EGF receptor than hTGF $\alpha$  (1). All members of the EGF family are characterized by the presence of six identically spaced cysteine residues, which form three intramolecular disulfide bridges. Together with some highly conserved glycine residues they are essential for the correct three-dimensional structure of the growth factor and for high affinity binding to the EGF receptor (2–4). Several other amino acids in hEGF like Leu-47 (Leu-48 in hTGF $\alpha$ ) and Arg-41 (Arg-42 in hTGF $\alpha$ ), which are not involved in maintaining structural integrity, have been shown to be crucial for high affinity binding to the EGF receptor, which suggests that they form part of the binding domain (5–9). The crystal structure of hEGF or hTGF $\alpha$  is not available, and most of the information on the structure of these growth factors has come from detailed <sup>1</sup>H NMR studies. Based on the observation that amino acids surrounding the second cysteine residue are in close contact with amino acids near the sixth cysteine residue, it has been postulated that Tyr-13/Leu-15/His-16 together with Arg-41/Gln-43/Leu-47 form the binding site in hEGF (10–12). The exact region involved in binding to the receptor is still not known, however, and this has hampered the design of receptor antagonists.

To gain more insight in the way hEGF and hTGF $\alpha$  bind to their receptor, we recently used the difference in binding affinity of these growth factors for the chicken EGF receptor as a model system. A total of 10 hEGF/hTGF $\alpha$  chimeras were constructed in which regions bordered by the highly conserved cysteine residues were exchanged, and their relative binding affinity for the chicken EGF receptor was assessed (13). Introduction of the region COOH-terminal of the sixth cysteine residue of hTGF $\alpha$  into hEGF appeared to be sufficient to confer high affinity binding characteristics to hEGF, and, in line with this, an exchange of the same region in hTGF $\alpha$  with the corresponding hEGF sequence caused hTGF $\alpha$  to lose its high affinity for the chicken EGF receptor. These data indicate that the COOH-terminal region in EGF receptor agonists plays an important role in receptor binding. In a recent <sup>1</sup>H NMR study (14), it has been shown that this region of hTGF $\alpha$  is flexible in the unbound molecule but that its mobility is strongly reduced upon receptor binding, which emphasizes again the role of the COOH-terminal domain in receptor-ligand interaction.

In the present study, we investigated in more detail which

\* This work was supported by grant KUNg3-4g3 from the Dutch Cancer Society. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ To whom correspondence should be addressed. Tel.: 31-80-652707; Fax: 31-80-652938.

<sup>1</sup> The abbreviations used are: hEGF, human epidermal growth factor; MEGF, mouse EGF; hTGF, human transforming growth factor; RP-HPLC, reverse-phase high pressure liquid chromatography; DMEM, Dulbecco's modified Eagle's medium; NCS, newborn calf serum; BES, *N,N*-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid.

amino acids in the COOH-terminal domain are responsible for high affinity binding to the chicken EGF receptor. To do so, the binding characteristics of an additional 7 hEGF/hTGF $\alpha$  exchange mutants and 3 COOH-terminal truncated forms of hEGF were investigated. A single amino acid exchange, Arg-45 to Ala, was found to be sufficient to generate an hEGF mutant with high affinity for the chicken EGF receptor.

#### EXPERIMENTAL PROCEDURES

**DNA Constructs**—The gene encoding the mature 50-amino acid sequence of human TGF $\alpha$  was made as previously described (13). The synthetic gene for human EGF was obtained from British Biotechnology (Oxford, United Kingdom). The genes were linked at the 5'-end to the sequence coding for the recognition sequence of the proteolytic enzyme factor X (Ile-Glu-Gly-Arg) (15). In former experiments (13), all constructs had been cloned into the pHema153 expression vector. Because in our hands a higher level of expression of biologically active protein was obtained using the pEZZ18 expression vector (Pharmacia, Uppsala, Sweden), the *EcoRI-SalI* fragments of pHema153/FX/EGF and pHema153/FX/TGF $\alpha$  were cloned into the corresponding sites of pEZZ18. In this way, the constructs encoding hEGF and hTGF $\alpha$  were placed in frame 3' of the sequence coding for the two synthetic IgG binding domains (so called Z domains) of pEZZ18. All further constructs were cloned into pEZZ18 using the *SalI* site at the 3'-end and either the *EcoRI* site or the *BamHI* site (which lies 9 base pairs downstream of *EcoRI*) at the 5'-end.

For the construction of T6TE and T6ET (for definition, see Fig. 1. and "Results"), the gene coding for hTGF $\alpha$  was cleaved at the sixth cysteine codon by *DraIII* and at the 3'-end by *SalI*. The gap was filled in using synthetic double-stranded oligonucleotides. For the construction of E6TE, hEGF was digested at the fourth cysteine codon by *SphI*, and T6TE was cleaved at the sixth cysteine codon by *DraIII*. The fragments were ligated to a double-stranded oligonucleotide spanning the region between the *SphI* site and the *DraIII* site. To generate E6ET, the *SphI* site and the *SalI* site of the hEGF construct were used, and the gap was filled in using two double-stranded oligonucleotides. DNA constructs that code for hEGF mutants truncated at the COOH-terminal end, EGF50, EGF49, and EGF48, were made by polymerase chain reaction using pEZZ/FX/EGF as a template. Three different antisense primers were designed such that the generated polymerase chain reaction products contained either the codon for Trp-50, Trp-49, or Lys-48 at their 3'-end followed by a stop codon and the *SalI* recognition site. For all constructs, the same sense primer was used, which annealed 5' of the *EcoRI* site of pEZZ/FX/EGF. Polymerase chain reaction products of the correct length were isolated and cloned into the modified *EcoRV* site of pT7blue T (Novagen Inc., Madison, WI) and subsequently transferred to pEZZ18 by *EcoRI-SalI* digestion. Point mutations in the hEGF gene were generated using the Altered Sites<sup>TM</sup> II *in vitro* mutagenesis system (Promega). All pEZZ18 mutant constructs were verified by DNA sequencing.

**Expression and Purification of Growth Factors**—Wild type and mutant growth factors were expressed as ZZ/FX/growth factor fusion protein in *Escherichia coli* KS474, a degP protease-deficient mutant (a generous gift from Drs. K. L. Strauch and J. Beckwith, Harvard University) (see Ref. 16). Bacteria were grown in 2YTE (16 g of bactotrypton, 10 g of yeast, 8 g of NaCl/liter) at 28 °C until an  $A_{600}$  of 1.5 was reached and the periplasmic proteins were isolated as described (17). After purification on IgG-Sepharose (Pharmacia), the amount of fusion protein recovered was measured by a competitive enzyme-linked immunosorbent assay using biotin-labeled protein A (19). The fusion proteins were digested by Factor X<sub>a</sub> coupled to CNBr-activated Sepharose, and the growth factors were purified by an additional run on IgG-Sepharose. Final purification was by RP-HPLC on a 15 × 0.39-cm Delta-Pak C<sub>18</sub> column (Millipore). Elution was carried out with a linear gradient of CH<sub>3</sub>CN in 0.1% trifluoroacetate at a flow rate of 1 ml/min. The biological activity in the column fractions (1 ml) was assayed on HER-14 cells in a binding competition assay with <sup>125</sup>I-mEGF (see below).

**Analysis of Fusion Proteins by SDS-Polyacrylamide Gel Electrophoresis and Western Blotting**—Aliquots of 10  $\mu$ l of unpurified periplasm were analyzed by gel electrophoresis on a 12.5% SDS-polyacrylamide gel in the absence or presence of 2%  $\beta$ -mercaptoethanol as a reducing agent. Proteins were transferred to nitrocellulose, and the Western blots were probed with a rat-anti-goat antibody linked to horseradish peroxidase. Enzyme activity was detected by incubation with tetramethylbenzidine/sodium diocylsulfosuccinate/H<sub>2</sub>O<sub>2</sub> in phosphate/citrate buffer (pH 5).

**Cell Lines**—NIH3T3 cells transfected with the human EGF receptor (HER-14 cells, 400,000 receptors/cell) or the chicken EGF receptor (CER-109 cells, 50,000 receptors/cell) were a generous gift from Dr. J. Schlessinger (New York University). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum (NCS).

**<sup>125</sup>I-mEGF Binding Competition Assays**—Mouse EGF (Bioproducts for Science Inc., Indianapolis, IN) was iodinated using enzymebeads (Bio-Rad) to a specific activity of ~500 Ci/mmol (18). HER-14 cells were grown to confluency in gelatinized 24-well dishes (1.8 cm<sup>2</sup>) and CER-109 cells in 6-well dishes (9.8 cm<sup>2</sup>). <sup>125</sup>I-mEGF (1 ng/ml for HER-14 and 40 ng/ml for CER-109) and serial dilutions of unlabeled growth factors were added to the cells in DMEM containing 15 mM HEPES (pH 7.7) and 10% NCS to inhibit nonspecific binding. After incubation for 2 h at room temperature, cells were washed twice with ice-cold phosphate-buffered saline, 0.1% bovine serum albumin, and once with ice-cold phosphate-buffered saline. The cells were incubated subsequently in 1% Triton X-100 for 1 h at room temperature prior to  $\gamma$ -counting. Experiments with HER-14 were performed in triplicate and with CER-109 in duplicate.

**Mitogenic Assays**—HER-14 cells were seeded in gelatinized 24-well dishes at a density of 60,000 cells/well in 1 ml of DMEM, 10% NCS. After 24 h of incubation, the medium was replaced by 0.9 ml of Ham's F12/DMEM (1:1) supplemented with 30 nM Na<sub>2</sub>SeO<sub>3</sub>, 10  $\mu$ g/ml human transferrin, and 0.5% bovine serum albumin. After an additional 48 h of incubation, serial dilutions of recombinant growth factors were added in 0.1 ml of DMEM containing 50 mM BES (pH 6.8). 8 h later, 0.5  $\mu$ Ci of [<sup>3</sup>H]thymidine was added in 0.1 ml of Ham's F12 medium. Incorporation of the tracer into cellular DNA was determined 24 h after growth factor addition. For this, cells were washed twice with phosphate-buffered saline and incubated with methanol at room temperature. After 15 min, the methanol was aspirated, and the cells were lysed in 1 ml of 0.2 N NaOH for 30 min at 37 °C as described (27). Radioactivity was determined by liquid scintillation counting. Experiments were performed in duplicate.

#### RESULTS

**Mutant Growth Factors**—In previous work (13), the COOH-terminal region in hTGF $\alpha$  was identified as an important domain for high affinity binding of hTGF $\alpha$  to the chicken EGF receptor. Introduction of this region into hEGF generated a chimeric growth factor (designated E6T) with high affinity for the chicken EGF receptor, whereas T6E, a chimera with TGF $\alpha$  sequences NH<sub>2</sub>-terminal and EGF sequences COOH-terminal of the sixth cysteine residue, has a low affinity. In the present study, the importance of specific amino acids within the linear COOH-terminal domain was investigated in more detail. First, EGF/TGF $\alpha$  chimeras were constructed in which either the region between the sixth cysteine residue and the highly conserved Leu-47 (Leu-48 in hTGF $\alpha$ ) or the region COOH-terminal of Leu-47 was exchanged. In this way, four EGF/TGF $\alpha$  exchange mutants were generated designated E6ET, E6TE, T6ET, and T6TE (Fig. 1). Next, individual amino acids in the region between the sixth cysteine residue and Leu-47 in hEGF were systematically exchanged with the corresponding amino acids in hTGF $\alpha$ , making the hEGF point mutants Q43E, Y44H, and R45A (Fig. 1). In addition, hEGF deletion mutants EGF50, EGF49, and EGF48 were constructed to evaluate the role of the relatively long COOH-terminal tail of hEGF (KWWELR) versus the much shorter tail of hTGF $\alpha$  (LA).

**Expression and Purification of Recombinant Growth Factors**—The expression of ZZ/FX/growth factor fusion protein in the periplasm was analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting, and the total amount of IgG binding activity in the periplasm was measured by a competitive enzyme-linked immunosorbent assay (19). The levels of expression of wild type and mutant growth factors appeared to be similar on Western blot as shown in Fig. 2 for wild type hEGF and the hEGF point mutants Q43E, Y44H, and R45A. The total amount of IgG binding activity in the periplasm ranged from 5 to 10  $\mu$ g/ml using protein A (Sigma) as a standard. Additional bands of higher molecular weight were present




FIG. 1. Schematic representation of mutant growth factors. Amino acids COOH-terminal of the sixth cysteine residue are indicated: circles, hEGF-derived amino acids; boxes, hTGF $\alpha$ -derived amino acids; diamonds, the conserved sixth cysteine residue and Leu-47 (Leu-48 in hTGF $\alpha$ ). The sequence NH<sub>2</sub>-terminal of the sixth cysteine residue is either hEGF (E) or hTGF $\alpha$  (T).




FIG. 2. Identification of ZZ/FX/growth factor fusion proteins by SDS-polyacrylamide gel electrophoresis and Western blotting. Aliquots of 10  $\mu$ l of unpurified periplasm were run on a 12.5% SDS-polyacrylamide gel under non-reducing (A) or reducing (B) conditions. Proteins were transferred to nitrocellulose, and the Western blots were probed with rat-anti-goat antibody linked to horseradish peroxidase: wild type hEGF, lanes 1 and 6; Q43E, lanes 2 and 7; Y44H, lanes 3 and 8; R45A, lanes 4 and 9; control periplasm (pEZZ18 without insert), lane 5.

on Western blot but disappeared under reducing conditions, indicating the presence of a small amount of (inactive) multimeric forms of the growth factor fusion proteins. One unidentified band of ~24 kDa, also present in control periplasm (pEZZ18 without insert), is thought to be due to nonspecific binding of IgG-peroxidase. Wild type and mutant growth factors were purified as described under "Experimental Procedures," and the presence of fusion protein or growth factor activity after each purification step was monitored by Western blotting, protein A enzyme-linked immunosorbent assay, and/or <sup>125</sup>I-mEGF binding competition assay. The growth factors were finally purified by RP-HPLC using a linear gradient of CH<sub>3</sub>CN in 0.1% trifluoroacetate (Fig. 3A). Fractions were analyzed for biological activity in a binding competition assay with <sup>125</sup>I-mEGF (Fig. 3B). In general, one major (peak I) and




FIG. 3. RP-HPLC chromatogram of the hEGF point mutant Q43E (A) and biological activity in the RP-HPLC fractions (B). Elution was carried out with a linear gradient of CH<sub>3</sub>CN in 0.1% trifluoroacetate at a flow rate of 1 ml/min. Biological activity present in the column fractions was determined in a binding competition assay with <sup>125</sup>I-mEGF.

two minor (peak IIa/b) biologically active products eluted between 25 and 35% CH<sub>3</sub>CN. When peak I and peak IIa/b were assayed separately (as was done for EGF50 and R45A), no differences were detected in their relative affinity for the chicken EGF receptor. With all other growth factors, peaks I and IIa/b were pooled. The identity of peaks I and IIa/b was not established, but it is assumed that the major peak represents "unmodified" growth factor, whereas the two minor peaks may represent chemically modified products or NH<sub>2</sub>-terminally truncated forms (2). Truncations at the COOH-terminal end are less likely since none of the biologically active peaks identified in EGF50 coeluted with those of EGF49 or EGF48 on the RP-HPLC column. Degradation of EGF upon storage has been reported to involve oxidation of Met-21, deamination of Asn-1 and/or succinimide formation of Asp-11 (2, 20). Oxidation of Met-21 and NH<sub>2</sub>-terminal deletions up to three amino acids does not significantly alter the biological activity of EGF (2).

<sup>125</sup>I-mEGF Binding Competition Assays on HER-14 and CER-109—To determine the binding affinity of the mutant growth factors for the human EGF receptor, the total binding activity present under peak I and peak IIa/b was measured in a <sup>125</sup>I-mEGF binding competition assay on HER-14 cells. Wild type mEGF (Bioproducts for Science Inc., Indianapolis, IN) was used as a standard, and the binding activity of the mutant growth factors was expressed as ng mEGF equivalents. The ratio between binding activity and the amount of protein rep-

TABLE I

## Binding affinities of hEGF mutants for the human EGF receptor

The ratio (R) between binding activity present under peaks I and IIa/b in the RP-HPLC chromatogram (ng mEGF equivalents) and the amount of protein represented by the peak area (mm<sup>2</sup>) was calculated for each mutant as well as for wild type mEGF (Bioproducts for Science Inc., Indianapolis, IN). The binding affinities of the mutant growth factors are expressed as percentage of wild type mEGF: R(mutant)/R(wild type) × 100%.

hEGF species	Binding affinity	
	% of wild type	
Wild type mEGF		100
EGF48		46
EGF49		124
EGF50 (peak I)		106
EGF50 (peak IIa/b)		106
Q43E		90
Y44H		117
R45A (peak I)		96
R45A (peak IIa/b)		124

resented by the peak area (absorption at 229 nm) was then calculated and compared with the ratio obtained with wild type mEGF (Table I). For most of the mutant growth factors the binding affinity was calculated to be close to the binding affinity of mEGF. Only the affinity of EGF48 was approximately 2-fold lower. No such data are available for the exchange mutants E6ET, E6TE, T6ET, and T6TE.

To determine the differential binding characteristics of the mutant growth factors for the human and the chicken EGF receptors, all recombinant proteins were eventually calibrated to give the same 50% competition of <sup>125</sup>I-mEGF binding to HER-14 cells as wild type mEGF. An example of this is shown in Fig. 4 for the EGF point mutants Q43E, Y44H and R45A.

**E6ET, E6TE, T6ET, and T6TE**—After calibration on HER-14 cells, the relative affinity of the mutant growth factors for the chicken EGF receptor was, subsequently, compared with the affinity of wild type hTGF $\alpha$  and hEGF. Replacement of the region between the sixth cysteine residue and Leu-47 in hEGF for the corresponding region in hTGF $\alpha$  (E6TE), was sufficient to increase the affinity of hEGF for the chicken EGF receptor to the level of hTGF $\alpha$  (Fig. 5A). Interestingly, also the region COOH-terminal of Leu-47 influenced the affinity of hEGF for the chicken EGF receptor. Replacement of the relatively long COOH-terminal tail in hEGF (KWWELR) for the much shorter corresponding region in hTGF $\alpha$  (LA) resulting in E6ET, caused a substantial increase in binding affinity for CER-109 cells. The increase in affinity was even larger when this region was replaced in T6E making T6ET; in contrast, T6E binds with a similar low affinity to the chicken EGF receptor as wild type hEGF (13).

**EGF50, EGF49, and EGF48**—One striking difference between hEGF and E6ET is the relatively long COOH-terminal tail (KWWELR) in hEGF as compared to a short tail (LA) in E6ET (and hTGF $\alpha$ ). To investigate whether this difference in tail length determines the difference in affinity between hEGF and E6ET, COOH-terminally truncated forms of hEGF were prepared. Deletion of three COOH-terminal amino acids ELR of hEGF (EGF50) caused a 4-fold increase in relative affinity for the chicken EGF receptor similar as seen with E6ET. Upon additional deletion (EGF49 and EGF48), however, this initial gain in affinity was lost (Fig. 5B).

**Q43E, Y44H, and R45A**—Of all modifications of hEGF tested thus far in this study, replacement of the region between the sixth cysteine residue and Leu-47 with the corresponding hTGF $\alpha$  sequence (E6TE) gave the largest increase in binding affinity. This region in hEGF differs from hTGF $\alpha$  only by three amino acids. To determine the individual role of these residues





FIG. 4. Inhibition of binding of <sup>125</sup>I-mEGF to HER-14. The binding activity of the mutant growth factors was calibrated to give the same competition of binding of <sup>125</sup>I-mEGF to HER-14 as wild type mEGF. Representative curves of the hEGF point mutants Q43E, Y44H, and R45A are shown after the final calibration. Experiments were repeated at least three times.

in high affinity binding to the chicken EGF receptor, each amino acid in this region in hEGF was successively exchanged with the corresponding amino acid in hTGF $\alpha$ . In this way, the point mutants Q43E, Y44H, and R45A were generated. Mutation of glutamine on position 43 to glutamate or mutation of tyrosine on position 44 to histidine hardly affected the relative affinity of hEGF for the chicken EGF receptor. However, exchanging arginine on position 45 in hEGF with alanine in hTGF $\alpha$  generated a hEGF mutant with a similar relative affinity for the chicken EGF receptor as hTGF $\alpha$  (Fig. 5C). Also, the absolute affinity of R45A for the chicken EGF receptor will be close to hTGF $\alpha$  since its affinity for the human EGF receptor was estimated to be similar to wild type mEGF (Table I).

**Mitogenic Activity**—To test whether the mutant growth factors are biologically active, HER-14 cells rather than CER-109 cells were used. We have noticed that wild type hEGF and hTGF $\alpha$  are equally mitogenic on CER-109 cells, whereas clear differences were observed using primary chicken adipocyte precursor cells.<sup>2</sup> The presence of endogenous mEGF receptors (3,000–10,000 receptors/cell) might cause a potentiation of the mitogenic response to growth factors that have a low affinity for the chicken EGF receptor but a high affinity for the mEGF receptor. Therefore, mitogenic assays on CER-109 cells are of limited value.


Because the binding affinity of all recombinant proteins was calibrated based on their ability to give 50% competition of <sup>125</sup>I-mEGF binding to HER-14 cells, any difference in relative mitogenic activity is most easily detected on the same cells. In Fig. 6 is shown that all growth factors were biologically active when tested for their ability to stimulate [<sup>3</sup>H]thymidine incorporation into serum-starved HER-14 cells. Most of the mutant growth factors were similarly active as wild type hEGF or hTGF $\alpha$ , but one mutant, EGF48, induced a slightly higher mitogenic response. The absolute affinity of EGF48, however, was calculated to be ~2-fold lower than the affinity of the wild type growth factors (Table I). We therefore expect that EGF48 will induce a similar mitogenic response as wild type hEGF when assayed on a protein basis. Loss of binding affinity without a concomitant decrease in mitogenic activity has been reported before by Walker *et al.* (5) for mEGF in which Leu-47

<sup>2</sup> M. L. M. van de Poll, A. E. G. Lenferink, M. J. H. van Vugt, E. J. J. van Zoelen, and S. Butterwith, unpublished results.



**FIG. 5. Inhibition of binding of  $^{125}\text{I}$ -mEGF to CER-109 by hEGF/hTGF $\alpha$  mutants.** The binding activity of the mutant growth factors was calibrated based on their ability to give 50% competition of  $^{125}\text{I}$ -mEGF binding to HER-14 (see Fig. 4). Their relative affinity for the chicken EGF receptor was subsequently measured in a binding competition assay on CER-109. The concentrations of the growth factors are thus expressed as ng mEGF equivalents/ml. Representative curves of at least three experiments are shown.

was mutated to Ala. In data to be published elsewhere, we will show that, even on a protein basis, some of the hEGF/hTGF $\alpha$  chimeras constructed previously by us (13) are truly superagonistic for HER-14 when compared with wild type hEGF or hTGF $\alpha$ .



**FIG. 6. Mitogenic response of HER-14.** The relative mitogenic activity of the mutant growth factors for HER-14 was assessed by measuring  $^3\text{H}$ thymidine incorporation into serum-starved cells 24 h after growth factor addition. Radioactivity incorporated in the presence of 10% NCS was  $197,600 \pm 6,000$  cpm in A and  $217,200 \pm 3,000$  cpm in B. Radioactivity incorporated in control cells (without growth factor addition) was  $26,300 \pm 1,800$  cpm in A and  $61,500 \pm 4,700$  cpm in B. Representative curves of at least three experiments are shown.

#### DISCUSSION

Mammalian EGF and TGF $\alpha$  bind with similar high affinity to the human EGF receptor, but their affinity toward the chicken EGF receptor differs substantially (1). Human EGF has a 10–50-fold lower affinity for the chicken EGF receptor than human TGF $\alpha$ , and the affinity of mouse EGF is ~5-fold lower than of human EGF (1, 13). We have previously used the differential binding characteristics of hEGF and hTGF $\alpha$  as a model to study ligand-receptor interactions (13). A total of 10 chimeras of hEGF and hTGF $\alpha$  were constructed, and it was found that chimeras with hTGF $\alpha$  sequences COOH-terminal of the sixth cysteine residue all had a similar high affinity for the avian EGF receptor as wild type hTGF $\alpha$ , whereas those having hEGF sequences in this region showed EGF-like binding characteristics. This indicates the importance of the COOH-terminal domain in discriminating between hEGF and hTGF $\alpha$ .

To identify amino acids involved in high affinity binding to the EGF receptor, a detailed analysis of the COOH-terminal domain of hEGF was made in the present study. Here, we show that the low affinity of human EGF for the avian EGF receptor is mainly due to the presence of arginine on position 45. Re-

placement of the positively charged Arg-45 for alanine, the corresponding amino acid in hTGF $\alpha$ , was sufficient to generate a hEGF mutant with high affinity for the chicken EGF receptor. Thus far, point mutation studies of the carboxyl-terminal region of hEGF and hTGF $\alpha$  have focused mainly on the highly conserved Asp-46 and Leu-47 (Asp-47 and Leu-48 in hTGF $\alpha$ ). Leu-47 and (less stringently) Asp-46 have been shown to be crucial for receptor binding and activation (5, 7, 9, 12). By using a domain exchange strategy, however, a systematic survey of the importance of non-conserved amino acids can be made. The present finding that Arg-45 discriminates between hEGF and hTGF $\alpha$  with respect to their affinity for the chicken EGF receptor, implicates that this amino acid lies close to or forms part of the receptor recognition site.

Lax *et al.* (21) analyzed the differential binding characteristics of the human and chicken EGF receptor using a domain-exchange strategy, and they demonstrated that domain III of the EGF receptor extracellular domain is most important for ligand recognition. Within this region the sequence between amino acids 351 and 364 was found to be the epitope recognized by ligand-competitive monoclonal antibodies (22). The participation of this epitope in the formation of a ligand binding site, however, was recently questioned since exchange of this region in the human EGF receptor for the corresponding sequence in the chicken EGF receptor did not alter the affinity of mouse EGF or human TGF $\alpha$  for the receptor (23). On the other hand, one might expect that the epitope recognized by an antibody that competes with the natural ligand for binding to the receptor lies close to the ligand binding site of the receptor. Immediately COOH-terminal of the epitope two lysine residues are found in the chicken EGF receptor that are not conserved in the human EGF receptor (24). For one of these lysine residues, a conservative replacement (Arg) is found in the murine EGF receptor; this amino acid is, therefore, less likely to discriminate between the chicken and the mammalian EGF receptor. The second lysine residue, however, is only found in the chicken EGF receptor, whereas in the human EGF receptor this positively charged amino acid is replaced by a negatively charged glutamate. We hypothesize that the lysine residue on position 367 in the chicken EGF receptor lies close to or forms part of the ligand binding domain and that the positively charged Arg-45 in the putative receptor recognition site of hEGF prohibits the interaction of hEGF with the chicken EGF receptor due to electrostatic repulsion.

Other positively charged amino acids in hEGF that might interfere with ligand-receptor interaction, are Lys-48 and Arg-53 in the carboxyl-terminal tail of hEGF. Replacement of this region in hEGF (KWWELR) for the corresponding uncharged sequence in hTGF $\alpha$  (LA), making E6ET, caused an increase in binding affinity. A similar improvement of binding affinity was found upon truncation of the carboxyl-terminal tripeptide ELR (EGF50) removing Arg-53 as the COOH-terminal amino acid. Additional deletion of Trp-50, however, resulted in a decrease in affinity for the chicken EGF receptor. Besides a difference in charge distribution, there is also a difference between hEGF and hTGF $\alpha$  in conformation of the COOH-terminal tail. In hEGF, this region adopts an  $\alpha$ -helix conformation involving Leu-47–Glu-51, whereas in hTGF $\alpha$  the COOH-terminal dipeptide is flexible in solution and lacks a defined structure (10, 14, 25). The  $\alpha$ -helix in hEGF has an amphipatic character with Lys-48 and Glu-51 on the hydrophilic site and Leu-47/Trp-50 and Trp-49/Leu-52 on the hydrophobic site. In addition, Trp-50 interacts with other hydrophobic amino acids in the protein such as Val-34 and Tyr-37 (10). One might speculate that in EGF50 the carboxyl-terminal tail

can still adopt an  $\alpha$ -helix conformation, which is stabilized by hydrogen bond formation between Leu-47 and Trp-50 as well as by VanderWaals interactions between Trp-50 and other hydrophobic side chains. In contrast to EGF50, no  $\alpha$ -helix structure will be formed in EGF49 or EGF48. The relatively high binding affinity of EGF50 for the chicken EGF receptor suggests that  $\alpha$ -helix formation of the carboxyl-terminal tail of hEGF will prevent the positively charged Lys48 from interfering with ligand-receptor interaction, whereas it does interfere in the case of EGF49 and EGF48.

In conclusion, we propose a model in which positively charged amino acids close to or within the putative receptor recognition site of hEGF (Arg-45 and to a lesser extent Lys-48 and Arg-53) prohibit high affinity binding to the chicken EGF receptor due to electrostatic repulsion of positive charges in or near the putative binding domain of this receptor. Comparing the carboxyl-terminal sequences of EGF receptor agonists of different origin, the proposed model would predict that EGF derived from human, mouse, or rat will have a low affinity for the avian EGF receptor, whereas human and rat TGF $\alpha$  but also EGF from guinea pig will have a high affinity for the avian EGF receptor.

In addition to amino acids in the COOH-terminal domain, residues in other domains are thought to form part of the binding domain in EGF and TGF $\alpha$ .  $^1\text{H}$  NMR studies have shown, for instance, that amino acids near the sixth cysteine residue are in close contact with residues surrounding the second cysteine residue (10), and in a recent study Richter *et al.* (26) hypothesized that amino acids in the B-loop  $\beta$ -sheet determine the difference in binding affinity between human EGF and mouse EGF for the chicken EGF receptor. Perhaps EGF receptor agonists contain two distinct binding domains that each can bind one receptor monomer similar as seen for the interaction of human growth hormone with its receptor (28). Data in favor of this model have been discussed previously by Gullick (29). Additional studies will be necessary, however, to increase our understanding of the way EGF and TGF $\alpha$  interact with their receptor and to make the design of receptor antagonists feasible.

*Acknowledgments*—We are grateful to Dr. T. J. Benraad and J. J. T. M. Heuvel (Department of Experimental and Chemical Endocrinology, University Hospital, St. Radboud, The Netherlands) for the generous supply of  $^{125}\text{I}$ -mEGF.

#### REFERENCES

- Lax, I., Johnson, A., Howk, R., Sap, J., Bellot, F., Winkler, M., Ullrich, A., Vennstrom, B., Schlessinger, J., and Givol, D. (1988) *Mol. Cell. Biol.* **8**, 1970–1978
- Carpenter, G., and Wahl, M. I. (1991) in *Peptide Growth Factors and Their Receptors* (Sporn, M. B., and Roberts, A. B., eds) Vol. I, pp. 69–171, Springer-Verlag New York Inc., New York
- Prigent, S. A., and Lemoine, N. R. (1992) *Prog. Growth Factor Res.* **4**, 1–24
- Violand, B. N., Tou, J. S., Vineyard, B. D., Siegel, N. R., Smith, C. E., Pyla, P. D., Zobel, J. F., Toren, P. C., and Kolodziej, E. W. (1991) *Int. J. Pept. Protein Res.* **37**, 463–467
- Walker, F., Nice, E., Fabri, L., Moy, F. J., Liu, J., Wu, R., Scheraga, H. A., and Burgess, A. W. (1990) *Biochemistry* **29**, 10635–10640
- Matsunami, R. K., Campion, S. R., Niyogi, S. K., and Stevens, A. (1990) *FEBS Lett.* **264**, 105–108
- Lazar, E., Watanabe, S., Dalton, S., and Sporn, M. B. (1988) *Mol. Cell. Biol.* **8**, 1247–1252
- Engler, D. A., Montelione, G. T., and Niyogi, S. K. (1990) *FEBS Lett.* **271**, 47–50
- Campion, S. R., Tadaki, D. K., and Niyogi, S. K. (1992) *J. Cell. Biochem.* **50**, 35–42
- Hommel, U., Harvey, T. S., Driscoll, P. C., and Campbell, I. D. (1992) *J. Mol. Biol.* **227**, 271–282
- Richter, A., Conlan, J. W., Ward, M. E., Chamberlin, S. G., Alexander, P., Richards, N. G. J., and Davies, D. E. (1992) *Biochemistry* **31**, 9546–9554
- Field, J. A., Reid, R. H., Rieman, D. J., Page Kline, T., Sathe, G., Greig, R. G., and Anzano, M. A. (1992) *Biochem. J.* **283**, 91–98
- Kramer, R. H., Lenferink, A. E. G., Lammerts van Bueren-Koornneef, I., van der Meer, A., van de Poll, M. L. M., and van Zoelen, E. J. J. (1994) *J. Biol. Chem.* **269**, 8708–8711
- Hoyt, D. W., Harkins, R. N., Debanne, M. T., O'Connor-McCourt, M., and

- Sykes, B. D. (1994) *Biochemistry* **33**, 15283–15292
15. Nagai, K., and Thogersen, C. (1987) *Methods Enzymol.* **153**, 461–481
16. Strauch, K. L., Johnson, K., and Beckwith, J. (1989) *J. Bacteriol.* **171**, 2689–2696
17. Nilsson, B., and Abrahmsen, L. (1990) *Methods Enzymol.* **185**, 144–161
18. Kienhuis, C. B. M., Heuvel, J. J. T. M., Ross, H. A., Swinkels, L. M. J. W., Foekens, J. A., and Benraad, T. J. (1991) *Clin. Chem.* **37**, 1749–1755
19. Van Zoelen, E. J. J., Kramer, R. H., Van Reen, M. M. M., Veerkamp, J. H., and Ross, H. A. (1993) *Biochemistry* **32**, 6275–6280
20. Senderoff, R. I., Wootton, S. C., Boctor, A. M., Chen, T. M., Giordani, A. B., Julian, T. N., and Radebaugh, G. W. (1994) *Pharm. Res. (NY)* **11**, 1712–1720
21. Lax, I., Bellot, F., Howk, R., Ullrich, A., Givol, D., and Schlessinger, J. (1989) *EMBO J.* **8**, 421–427
22. Wu, D., Wang, L., Sato, G. H., West, K. A., Harris, W. R., Crabb, J. W., and Sato, J. D. (1989) *J. Biol. Chem.* **264**, 17469–17475
23. Brown, P. M., Debanne, M. T., Grothe, S., Bergsma, D., Caron, M., Kay, C., and O'Connor-McCourt, M. D. (1994) *Eur. J. Biochem.* **225**, 223–233
24. Avivi, A., Lax, I., Ullrich, A., Schlessinger, J., Givol, D., and Morse, B. (1991) *Oncogene* **6**, 673–676
25. Gallay, J., Vincent, M., De la Sierra, I. M. L., Alvarez, J., Ubieta, R., Madrazo, J., and Padron, G. (1993) *Eur. J. Biochem.* **211**, 213–219
26. Richter, A., Drummond, D. R., MacGarvie, J., Puiddicombe, S. M., Chamberlin, S. G., and Davies, D. E. (1995) *J. Biol. Chem.* **270**, 1612–1616
27. Van Zoelen, E. J. J., Van Oostwaard, T. M. J., Van der Saag, P. T., and De Laat, S. E. (1985) *J. Cell. Physiol.* **123**, 151–160
28. Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., Goeddel, D. V., and Wells, J. A. (1992) *Science* **256**, 1677–1680
29. Gullick, W. J. (1994) *Eur. J. Cancer* **30**, 2186